Background: Serum bilirubin is negatively associated with the development of coronary heart disease. In the present study, we have focused on the analysis of intima-media thickness (IMT) of the common carotid artery in hyper- and normobilirubinemic subjects. Methods: The study was performed on 111 men without manifested atherosclerosis. In all subjects, complete biochemical tests were determined along with the examination of IMT by carotid ultrasound. Results: The mean IMT in hyperbilirubinemic subjects as compared with controls was substantially lower (p = 0.017), and hyperbilirubinemic men also had very low age-adjusted prevalence odds ratios for having IMT above the 50th percentiles of controls, even after adjustment for selected vascular risk factors (p = 0.034). Conclusions: In the present study, we demonstrate the inverse relationship between serum bilirubin and IMT in healthy men.

Keywords:
Carotid atherosclerosis, Bilirubin, Gilbert syndrome
1.
Stocker R, Yamamoto Y, McDonagh A, Glazer AN, Ames NB: Bilirubin is an antioxidant of possible physiological importance. Science 1987;235:1043–1046.
2.
Wu TW, Fung KP, Yang CC: Unconjugated bilirubin inhibits the oxidation of human low density lipoprotein better than Trolox. Life Sci 1994;54:477–481.
3.
Baranano DE, Rao M, Ferris CD, Snyder SH: Biliverdin reductase: a major physiologic cytoprotectant. Proc Natl Acad Sci USA 2002;99:16093–16098.
4.
Novotný L, Vítek L: Inverse relationship between serum bilirubin and atherosclerosis in men: a meta-analysis of published studies. Exp Biol Med 2003;228:568–571.
5.
Vítek L, Jirsa M Jr, Brodanová M, Kaláb M, Mareček Z, Danzig V, Novotný L, Kotal P: Gilbert syndrome and ischemic heart disease: a protective effect of elevated bilirubin levels. Atherosclerosis 2002;16:449–456.
6.
Nicholl P, Mikhailidis DP, Hamilton G, Winder AF: Bilirubin and peripheral vascular disease (abstract). Br J Surg 1995;82:1561–1562.
7.
Krijgsman B, Papadakis JA, Ganotakis ES, Mikhailidis DP, Hamilton G: The effect of peripheral vascular disease on the serum levels of natural anti-oxidants: bilirubin and albumin. Int Angiol 2002;21:44–52.
8.
Cerne D, Ledinski G, Kager G, Greilberger J, Wang X, Jurgens G: Comparison of laboratory parameters as risk factors for the presence and the extent of coronary or carotid atherosclerosis: the significance of apolipoprotein B to apolipoprotein all ratio. Clin Chem Lab Med 2000;38:529–538.
9.
Ishizaka N, Ishizaka Y, Takahashi E, Yamakado M, Hashimoto H: High serum bilirubin level is inversely associated with the presence of carotid plaque. Stroke 2001;32:580–583.
10.
Holaj R, Spáčil J, Petrášek J, Malík J, Haas T, Aschermann M: Intima-media thickness of the common carotid artery is the significant predictor of angiographically proven coronary artery disease. Can J Cardiol 2003;19:670–679.
11.
Breimer LH, Wannamethee G, Ebrahim S, Shaper AG: Serum bilirubin and risk of ischemic heart disease in middle-aged British men. Clin Chem 1995;41:1504–1508.
12.
Hopkins PN, Wu LL, Hunt SC, James BC, Vincent GM, Williams RR: Higher serum bilirubin is associated with decreased risk for early familial coronary artery disease. Arterioscler Thromb Vasc Biol 1996;16:250–255.
13.
Djousse L, Levy D, Cupples LA, Evans JC, D’Agostino RB, Ellison RC: Total serum bilirubin and risk of cardiovascular disease in the Framingham Offspring Study. Am J Cardiol 2001;87:1196–1200.
14.
Whitfield JB, Zhu G, Nestler JE, Heath AC, Martin NG: Genetic covariation between serum gamma-glutamyltransferase activity and cardiovascular risk factors. Clin Chem 2002;48:1426–1431.
15.
Ko GT, Chan JC, Woo J, Lau E, Yeung VT, Chow CC, Li JK, So WY, Cockram CS: Serum bilirubin and cardiovascular risk factors in a Chinese population. J Cardiovasc Risk 1996;3:459–463.
16.
Papadakis JA, Ganotakis ES, Jagroop IA, Mikhailidis DP, Winder AF: Effect of hypertension and its treatment on lipid, lipoprotein(a), fibrinogen, and bilirubin levels in patients referred for dyslipidemia. Am J Hypertens 1999;12:673–681.
17.
Feigin VL, Anderson CS, Mhurchu CN: Systemic inflammation, endothelial dysfunction, dietaryfatty acidsand micronutrients as risk factors for stroke: a selective review. Cerebrovasc Dis 2002;13:219–224.
18.
Kritchevsky SB, Shimakawa T, Tell GS, Dennis B, Carpenter M, Eckfeldt JH, Peacher-Ryan H, Heiss G: Dietary antioxidants and carotid artery wall thickness. The ARIC Study. Atherosclerosis Risk in Communities Study. Circulation 1995;92:2142–2150.
© 2006 S. Karger AG, Basel
2006
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.